Intas Pharmaceuticals has launched its cut-price etanercept, a biosimilar version of Amgen's TNF-inhibitor Enbrel, on the Indian market.
Intas' etanercept (marketed as Intacept), available in two strengths 25mg in 0.5ml and 50mg in 1.0ml preservative-free solution, joins Cipla's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?